{
    "title": "Development of a Liver Disease-Specific Large Language Model Chat Interface using Retrieval Augmented Generation",
    "url": "https://openalex.org/W4388594005",
    "year": 2023,
    "authors": [
        {
            "id": "https://openalex.org/A2130019586",
            "name": "Jin Ge",
            "affiliations": [
                "University of California, San Francisco"
            ]
        },
        {
            "id": "https://openalex.org/A2112471910",
            "name": "Steve Sun",
            "affiliations": [
                "University of California, San Francisco",
                "University of San Francisco"
            ]
        },
        {
            "id": "https://openalex.org/A2187066148",
            "name": "Joseph Owens",
            "affiliations": [
                "University of San Francisco",
                "University of California, San Francisco"
            ]
        },
        {
            "id": "https://openalex.org/A2147500098",
            "name": "Victor Galvez",
            "affiliations": [
                "University of California, San Francisco",
                "University of San Francisco"
            ]
        },
        {
            "id": "https://openalex.org/A155093859",
            "name": "Oksana Gologorskaya",
            "affiliations": [
                "University of San Francisco",
                "University of California, San Francisco"
            ]
        },
        {
            "id": "https://openalex.org/A2129142352",
            "name": "Jennifer C. Lai",
            "affiliations": [
                "University of California, San Francisco"
            ]
        },
        {
            "id": "https://openalex.org/A1967775094",
            "name": "Mark J. Pletcher",
            "affiliations": [
                "University of California, San Francisco"
            ]
        },
        {
            "id": "https://openalex.org/A2522976512",
            "name": "Ki Lai",
            "affiliations": [
                "University of San Francisco",
                "University of California, San Francisco"
            ]
        },
        {
            "id": "https://openalex.org/A2130019586",
            "name": "Jin Ge",
            "affiliations": [
                "University of California, San Francisco"
            ]
        },
        {
            "id": "https://openalex.org/A2112471910",
            "name": "Steve Sun",
            "affiliations": []
        },
        {
            "id": "https://openalex.org/A2187066148",
            "name": "Joseph Owens",
            "affiliations": []
        },
        {
            "id": "https://openalex.org/A2147500098",
            "name": "Victor Galvez",
            "affiliations": []
        },
        {
            "id": "https://openalex.org/A155093859",
            "name": "Oksana Gologorskaya",
            "affiliations": [
                null
            ]
        },
        {
            "id": "https://openalex.org/A2129142352",
            "name": "Jennifer C. Lai",
            "affiliations": [
                "University of California, San Francisco"
            ]
        },
        {
            "id": "https://openalex.org/A1967775094",
            "name": "Mark J. Pletcher",
            "affiliations": [
                "University of California, San Francisco"
            ]
        },
        {
            "id": "https://openalex.org/A2522976512",
            "name": "Ki Lai",
            "affiliations": []
        }
    ],
    "references": [
        "https://openalex.org/W4386356152",
        "https://openalex.org/W4361298749",
        "https://openalex.org/W4384561181",
        "https://openalex.org/W4387145532",
        "https://openalex.org/W4360993412",
        "https://openalex.org/W6810242208",
        "https://openalex.org/W2479527281",
        "https://openalex.org/W4379769651",
        "https://openalex.org/W4389868615",
        "https://openalex.org/W4384702065",
        "https://openalex.org/W4387640749",
        "https://openalex.org/W2992005260",
        "https://openalex.org/W4353016766",
        "https://openalex.org/W2796067155",
        "https://openalex.org/W4377011124",
        "https://openalex.org/W4388497846",
        "https://openalex.org/W4384457683",
        "https://openalex.org/W3037480398",
        "https://openalex.org/W2884533191",
        "https://openalex.org/W2186770976",
        "https://openalex.org/W2961821163",
        "https://openalex.org/W3159795713",
        "https://openalex.org/W2995815973",
        "https://openalex.org/W4288077670",
        "https://openalex.org/W2082390213",
        "https://openalex.org/W2105932465",
        "https://openalex.org/W2173698250",
        "https://openalex.org/W2791839818",
        "https://openalex.org/W2890778396",
        "https://openalex.org/W4211191129",
        "https://openalex.org/W2116578643",
        "https://openalex.org/W94062176",
        "https://openalex.org/W2089416968",
        "https://openalex.org/W2130106335",
        "https://openalex.org/W2164060120",
        "https://openalex.org/W3181395511",
        "https://openalex.org/W4318923555",
        "https://openalex.org/W4210483174",
        "https://openalex.org/W4387865678",
        "https://openalex.org/W4382786306",
        "https://openalex.org/W2886703787",
        "https://openalex.org/W3196148322",
        "https://openalex.org/W4295048810",
        "https://openalex.org/W3087419935",
        "https://openalex.org/W3103618496",
        "https://openalex.org/W4297023433",
        "https://openalex.org/W2905728487",
        "https://openalex.org/W3212531300",
        "https://openalex.org/W4388485328",
        "https://openalex.org/W1574141134",
        "https://openalex.org/W4392362609",
        "https://openalex.org/W4391188705",
        "https://openalex.org/W4390191984",
        "https://openalex.org/W2108424589",
        "https://openalex.org/W4378192633"
    ],
    "abstract": "Abstract Background Large language models (LLMs) have significant capabilities in clinical information processing tasks. Commercially available LLMs, however, are not optimized for clinical uses and are prone to generating incorrect or hallucinatory information. Retrieval-augmented generation (RAG) is an enterprise architecture that allows embedding of customized data into LLMs. This approach “specializes” the LLMs and is thought to reduce hallucinations. Methods We developed “LiVersa,” a liver disease-specific LLM, by using our institution’s protected health information (PHI)-complaint text embedding and LLM platform, “Versa.” We conducted RAG on 30 publicly available American Association for the Study of Liver Diseases (AASLD) guidelines and guidance documents to be incorporated into LiVersa. We evaluated LiVersa’s performance by comparing its responses versus those of trainees from a previously published knowledge assessment study regarding hepatitis B (HBV) treatment and hepatocellular carcinoma (HCC) surveillance. Results LiVersa answered all 10 questions correctly when forced to provide a “yes” or “no” answer. Full detailed responses with justifications and rationales, however, were not completely correct for three of the questions. Discussions In this study, we demonstrated the ability to build disease-specific and PHI-compliant LLMs using RAG. While our LLM, LiVersa, demonstrated more specificity in answering questions related to clinical hepatology – there were some knowledge deficiencies due to limitations set by the number and types of documents used for RAG. The LiVersa prototype, however, is a proof of concept for utilizing RAG to customize LLMs for clinical uses and a potential strategy to realize personalized medicine in the future.",
    "full_text": "Dev elopmen t of a Liv er Disease-Specifi c Lar g e Languag e Model Cha t In t erf ace using R etriev al \nAugmen t ed Gene r a tion  \n \nJin Ge , MD , M B A 1 ; S t ev e Sun 2 ; Joseph O w ens, PhD 2 ; Vict or Galve z 2 ; Ok sana Golo gor sk a ya, MS 2,3 ; Jennif er \nC. Lai, MD , MB A 1 ; M ark J . Plet ch er , MD , MPH 4 ; Ki Lai, MS 2  \n \n1  Division of  Gas troenter ology and He patology , Department of Medicin e, Univ e r sit y of Cali f ornia – San \nFr ancisc o , San Fr a ncisc o , CA  \n2  UCSF Health Inf orma ti on T echnology, Univ er sity  of Calif ornia – San Fr ancisco , Sa n Fr ancisc o , CA  \n3 Bak ar Comput ational H ealt h Sciences In s titu t e , Univ e r sity of Calif ornia – San Fr a ncisc o , San Fr ancisc o, \nCA \n4 Department of Epidemiology and Biostatis tics, Univer sity of Calif ornia – San Fr an cisc o , San Fr ancisc o , \nCA \n \nFinancial/Gr an t Suppo rt:\n \nThe autho r s of this s tudy w e r e suppo rted  in part by the KL2TR001870 (Na tiona l Cen ter f or Adv ancing \nT r ansla t ional Scienc es, G e), P30DK02674 3 (UCSF Liv er Cen t er Gr a n t, Ge and Lai), UL1TR001872 (Na tional \nCen ter f or Adv ancing T r ansl a tion al Scienc es, Plet cher), and R01A G059183/K24AG080021 (Na tional \nIns ti tu t e on Aging , Lai).  The c ontent is solely the responsibility of th e auth or s and does not n ecessarily \nr eprese n t t he of ficial view s of the N a ti on al Ins ti tu t es of Heal th or an y oth er fundi ng ag encies.  The \nfunding ag encies pla yed no r ole in t he an alysis of the dat a o r the p r ep ar ation of th is manuscript.  \n \nAbbr evia tions:\n \nAASLD , Ameri c an Associ a ti on f or the St u dy of Liv er Diseases; APIs, applica ti on pr o gr amming in t erf aces ; \nFHIR, F a s t He alth c are I n ter op er abili ty R e sour ces; HB V , h ep a ti tis B; HCC, hepat ocel lular c a r cinoma; GAI, \ng enera tive ar tificial int elligence; GPT , g ener ativ e pre-tr ain ed trans f ormer ; LLMs, lar g e langua g e models ; \nPHI, pr o t ec t ed he alth inf ormation; RA G, retriev al-augme n ted g en era tion ; UCSF , Un iv er sity of Calif ornia, \nSan Fr ancisc o.  \n \nCorr esponden ce:  \n \nJin Ge , MD , M B A  \n513 P arnassus A v enue, S-357 \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nNOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.\nSan Fr ancisc o , CA 94143   \nE-mail: jin. g e@ucs f .edu  \nF ax: 415-476-0659 \n \nDisclosur es:  \n \nThe autho r s of this manuscript ha v e the f ollowing pot e n tial c onflicts of in teres t t o disclose:  \n-  Dr . Jin Ge r eceives r es ear ch suppo rt fr om  Mer ck and Co; and c onsu lts f or Ast ellas \nPharmaceuticals/Io t a Bioscienc es.  \n-\n Dr . Jennif er C. Lai r ece iv es resear ch supp ort fr om Lipocene a nd Vir Bio t echnologi e s; r eceives an \neduca tion gr a n t fr om N es t le Nu tri tion Sci ences; ser v es on a n advisory boa r d f or N ov o Nor disk; \nand c onsults f or G enfit, Thir d R ock V entu r es, and B oehri ng er Ing el heim.  \n \nW riting Assi s t ance: \n \nNone .  \n \nAuthor Con tributions:\n \nAutho r ship w as determine d using ICMJE r ec omme ndations .  \nGe:  Concept a nd design; d a ta extr ac tion; analysis and int e rpr e ta ti on of dat a; dr afti ng of manuscript; \ncritic al r evision of the manuscript f or imp ortant int ell ectual cont e n t ; s tudy super vi sion \nSun:  Dat a extraction ; analysis and i n terp ret ation of d a ta; criti c al r evision of th e ma nuscript f or important \nin tellec tual c o nt e n t  \nOwens: Concept and design; a nalysis and  in terpreta ti on of dat a; cri tic a l r evision of the manuscript f or \nimport a n t i nt ellec tual cont e n t  \nGalv e z:  An alysis and interpreta ti on of data; critical r evision of the man uscript f or import a n t i nt ellec tual \nc ont e n t  \nGolo gorsk ay a:  An alysis and int e rpr e ta ti o n of da t a ; criti c al r evision of th e manuscr ipt f or import a n t \nin tellec tual c o nt e n t  \nJ . Lai : Concept and d esign; critical r evisio n of the manuscript f or impor t a n t intelle ctual c o n tent; study \nsuper vision \nPlet cher : Concept and design ; critical r evi sion of the manuscript f or impor t a n t inte llectual cont e n t ; s tudy \nsuper vision \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nK. Lai: Concept and design; cri tical r evisio n of the manuscript f or impor t a n t intelle ctual c o n tent; study \nsuper vision \n \nAcknowledg emen ts:\n \n-  The autho r s thank th e UCSF AI Tig e r T eam, Ac ademic R es ear ch S er vices, R esea r c h Inf orma tion \nT echnology, and the Chancellor ’ s T ask F or ce f or Gen er ativ e A I f or thei r softw are d ev elopme n t, \nanalytical, and t echni c al suppo rt related t o th e use of V er sa API g at ew a y (the UCS F secur e \nimplementa tion of la r g e langu ag e mod el s and g enera tive AI via API g at ew a y), V ersa cha t (the \ncha t use r int e rf ace), and r el at ed d at a ass ets.  \n \nW or d Coun t:\n \n2,025 (without re f e r ences)   \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nAbs tr act:  \nBackgr ound:  Lar g e languag e mod els (LL Ms) ha v e signific an t capabili ties in clinic a l inf orma tion pr oc essing \nt ask s.  Commer cially a v aila ble LLMs, howev er , are not op timiz ed f or clinic al uses a nd ar e prone t o \ng enera ti ng inc or r ect o r hallucin a tory inf orma ti on.  R et riev al-augmented g en er atio n (RAG) is an \nent er prise a r chitectu r e th a t allo w s embe dding of cus t omiz ed dat a into LLMs.  Thi s appr oach “ specializ es”  \nthe LLMs and is thought to r e duce halluci na ti ons.  \nMethods:  W e dev eloped “LiV er sa, ” a liv e r disease-specific LLM, by using our ins tit ution’ s p r o t ec t ed \nhealth inf ormation (PHI)-c omplaint te x t e mbedding and LLM pla tf orm, “ V er sa. ”  W e c onduc t ed RA G on \n30 publicly a v ailable Ameri c an Associ a tio n f or the Study of Liv er Diseases (AASLD) guidelines and \nguidance documents to be inc o rporat ed i n to LiV er sa.  W e ev alu at ed LiV er sa ’ s performance by c omparing \nits r espons es v er sus th ose of tr ain ees fr o m a pr eviously published knowledg e asse ssmen t study \nr eg ar ding h epatitis B (HB V) treatment an d hepat oc ellular car cinoma (HCC) sur v eillance.   \nR esults:  LiV er sa answ e r ed all 10 que s tion s c orr ec tly when f or ced to pr ovide a “y es ” or “no” answ er .  Full \ndet ail ed r esp onses with jus tifica ti ons an d r a tion ales, how ever , wer e n ot c omple tely c orrect f or th r ee of \nthe que s tions .  \nDiscussions:  In t his s tudy, w e demo ns trated the abi lity  to build diseas e-specific and PHI-c omplian t LLMs \nusing RAG.  While ou r LLM, LiV er sa, dem ons trat ed more specificity in answ ering q ues tio ns r el at ed t o \nclinic al hep at ology – th er e were some kn owledg e d e ficiencies due t o limi t ations s et by the number an d \ntypes of documen ts us ed f or RAG.  The Li V er sa pr o t otyp e, how ev er , is a pr oof of concept f or utilizing \nRAG to cus tomiz e LLMs f or clinic al uses and a potential s trat egy t o r e aliz e per s ona liz ed medicine in th e \nfutur e .  \n \n \n  \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nIn tr oduction:  \nLar g e langua g e models (LLMs), such as OpenAI ’ s G enera tive Pr e-tr ai ned T r an s f or mer (GPT) f amily of \nmodels, ha v e d emons trat ed signific a n t capabiliti es in clinic al inf orma ti on pr ocessi ng t ask s, such as dat a \ne x tr actio n,\n1  summarizing liter ature, 2  c o nten t generation, 3  and p r edictive modeling . 4   Commer cially \na v ailable gener al-pu rpose LLMs, such as OpenA I’ s ChatGPT , how ev er , a r e tr aine d on publicly a v ailable \ndat a and no t optimiz ed f or clinic al uses . 5   This means tha t the ou tpu ts of publicly a v ailable LLMs when \npr ompt e d with clinic al qu es tio ns ma y include inc or r ec t, inc omple te, or hallucin at o ry inf orma tion. 6,7   \nDespit e these limi t ations, LLMs are thou gh t to ha v e signific a n t po t e n ti al in biome dic al and clinic al \napplica tions .  This is bec ause t he pr actic e  of modern medicine is highly c omple x e ndea v or with ever-\nincr easing amou n ts of knowledg e generat ed ye arly .\n8   F or inst anc e, it w as e s tim a te d that tw o pa per s \nw er e upl oade d t o PubM ed ev e ry minut e in 2016, 9  a figur e that has undoub t edly i ncr ease d in the sev e n \nyear s since.  N a ti onal pr ac tice societi es ha v e also responde d t o the ever-e x pandin g body  of clinic al \nknowledg e by dev eloping c omprehensive pr actice guideli nes.  F o r inst ance, the A meric an Associ a ti on of \nthe Stu dy of Liv er Diseases (AASLD) has i ssued guidelines and guida nce docume n t s f or 26 liv er diseases \nand c ondi tions, and tw o quali ty measure s c oncerning cirrhosis an d hep at ocellula r  c ar cinoma (HCC).\n10   \nMethods t o inc o rporat e medi c al li t era tu re, such as clinic al pr actic e guidelines an d guidance documents, \nin to LLM r esponses , the re f or e, r ep r ese n t  gr owing ar ea of int erest t o h elp g en er al- purpose LLMs bec om e \n“ specializ ed” f or clinic ally- f ocused applica tio ns.  \n \nCurr ently, the r e a r e th r e e g en er al app r oa ches and techniques t o allow LLM “ speci aliz ation:” 1. Fine- tune \nthe origina l LLM model, which is c omputa tio nally e xp ensiv e ;\n11,12  2. Pr ompting wit hin the LLM, which only \nacc ommodates small amoun ts of d a ta an d r equi r es itera tive user inpu t; 13–15  and 3.  R etriev al-augmented \ng enera ti on (RAG). 16–18   RAG is an ent erp ri se ar chi t ectu r e that augme n ts LLM abiliti es by adding an \ninf orma tion r e triev al s yst em t hat pr ovide s e x t ern al dat a , which then supplem ent a nd c ons train LLM \noutput .  In pr ac tice, this me ans th a t a d ataset, such as a c ompe ndium of clinic al practice guidelin es, is \nv ect o riz ed and e nc od ed using embeddin g models and then incorporat ed i nt o th e LLM by la y ering it on \nt op of th e LLM inf orma tion r e triev al and output p r ocesses .\n16    The theor e tic al adv ant ag es of RAG ar e \ntw o-f old: 1. Handling la r g e numb er s of documen ts t o pr ovide “ gr ound knowledge ” f or the LLM, and 2. \nDecr easing hallucin a tio ns by limiting the potential “ solution-space” f or LLM outpu ts.  This RAG appr o ach \nhas been proposed an d utiliz ed in o the r clinic al specialti es, such as g en er al medic ine and ur ol ogy.\n17,19, 20   \nExis ting RAG implem enta tions , how ev er , ha v e larg ely been on publicly a v ailable a nd not pr o t ec ted heal th \ninf orma tion [PHI]-c ompliant LLMs – the reby limiting permitt ed use in clini c al pr ac tice  \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \n \nIn this s tudy, w e u tiliz ed RA G t o c r e at e a pr o t oty pe liver diseas e-specific LLM, c alled “LiV er sa, ” within the \nUniv er sity of Calif ornia, San Fr a ncisc o’ s ( UCSF) PHI-c omplian t impleme n tation of Micr osoft Op enAI GPT \nf amily of LLM models, “ V er sa. ”  \n \nMethods:\n \nThis s tudy w as not c onside r ed hum an su bjects r es ear ch b ec aus e no human d at a or specimens wer e us ed.   \nConsequently, appr ov al fr om th e UCSF In s titu tional R eview Boa r d w as not so ugh t .   T o c ons truct our liver \ndisease-specific LLM (LiV er sa), w e used all a v ailable pr ovide r-f acing clinic al pr actice guidelines, guidanc e \ndocumen ts , and quali ty measure documen ts publish ed by AASLD on its w ebsite.\n10   W e e x cluded \nin troduction a nd ex ecu tiv e summary doc umen ts as t he c o nt e n t in th ese w e r e of t e n duplic ated in the \nc orresponding full-leng th ver sions (e. g., f or Wilson’ s Diseas e).  W e included bo th original \nguidelines/ guidance docume n ts and up d at es if both w e r e publicly a v ailabl e f or download on AASLD \nw ebsit e (e. g. , f or Chr onic Hep a titis B [H BV]).  P a tient-f acing and/ or out d at ed guid elines/ guidance \ndocumen ts were not includ ed in this s t u dy.  In t o t al, 30 docume n ts were r et riev e d t o be in c orporat e d \nin to the RA G pr oc ess (T able 1). \n \nW e utiliz ed ap plica tion p r ogr amming int e rf aces (APIs) pr ovided by the Micr osoft A zur e Op enAI Cognitive \nSear ch sui t e of t ools t o inc o rpora te th e A ASLD guidelines and documents f or RAG (Figur e 1).\n16   In the \npr e-pr oc essing phase, th e 30 AASLD guidelines and docume n ts in PDF f orma t w e re tr ans f orm ed int o \nembeddings using Micr osoft Azu r e Op en AI’ s AD A T ext Embedding V er sio n 2 mode l ( t e xt-em bed din g-ad a-\n002 ).  T e xt embeddings a r e numeri c al re pr ese nt ations of te x t where w or ds f or ph r ases ar e r ep r es ent ed \nas multi-dimensional v ec t or s .\n21,22   These embedding v ec t or s a r e th en st o r ed in a d a tabase with the \nMicr osoft Azure Cognitiv e S ear ch ser vice s.  During cha t int eractions with LiV er sa, user s’ pr ompts a r e \nc on v er ted int o emb eddings in r e al time u sing the same t ext-e mbe ddin g-ad a-002 model.  A sea r ch is then \nperf ormed on t he pr eviously pr oc essed vect o r dat ab ase of AASLD guidelines and documen ts t o find \nma t ch es f or the pr omp t embeddings.  Th e sear ch results fr om this se ar ch process ar e t hen passe d t o the \ngpt-35-tur bo  or gpt-4-32k  LLMs t o g ene rat e a c omple tion, which is the outpu t fr o m the LLM in the \nLiV er sa cha t interf ace.   \n \nW e pr e-set three sample qu estions int o “ Sample Questions” section of th e LiV er sa  in terf ace:  \n1.\n What are the indi c ations f or liv er tr anspl ant ation?  \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \n2.  Who should be screen ed f or chr onic hep a ti tis B?  \n3.  What is the r ecommended th er apy f or a pa ti ent with BCL C 0-A H CC  without porta l h ypert ensio n?    \n \nT o c ompar e LiV er sa’ s p erf ormance on fre e-f orm clinic al hepat ol ogy ques tio ns, w e c ompared its \nr espons es t o medi c al traine es’ r esp onses  in a pr eviously published c ase-vignette based knowledg e \nassessmen t qu estions on HB V t r e a tm ent and hep a tocellula r c ar cin oma (HCC) sur v eillance .\n23   W e chose \nthis set of questions because they ha ve a lso been ev alu a ted by the publicly a v aila ble Cha t GPT . 24   Prior t o \ninput int o LiV er sa, c ase-vignett es wer e e dit ed f or clari ty and appropri at eness wit h the goal of r etaining \nthe essenc e of the clinical scenario .  W e ask ed LiV er sa t o giv e bo th a full r esp onse  and a f or ced “yes” or \n“no” r esponse by appending th e pr ompt with “ Answ er y es or no” t o each inpu t ted  c ase-vignet te (Figur e \n2). \n \nR esults:\n \nThe user int e rf ace f or LiV er sa is shown in Figur e 2.  The int e rf ace is the same as t o the on e used f or \n“ V er sa Cha t ” (the cha t i n terf ace f or th e gener al-pur pose PHI-c omplia n t LLM imple men tation at UCSF), \ne x cept with t he d a ta sour ce b eing set to the “UCSF In t r anet : AASLD Clinic al Pr acti ce Guidelin es \n(Pr ot otype). ”  LiV er sa’ s r esp onses t o th e t hr ee sampl e questions a r e f e atured in T a ble 2.  LiV er sa’ s \nperf ormance on case-vignett e bas ed knowledg e assessme n t qu es tio ns on HB V tre a tme n t a nd HCC \nsur v eillance a r e f e a t ur e d in T able 3, Colu mns B and C.  The c orr ec t answ er s al ong with per ce n tag es of \ntr aine es who answ ered c or r ec tly per prio r s tudies a r e f eatured in T able 3, Column D .  LiV er sa answ er ed \nall 10 ques tio ns c or r ectly when f or ced t o pr ovide a “y es” or “no” answ er .  Ra tio nal es and jus tifica tions \nwithin the full answ er s , how ev er , were n ot c omple t ely c o rrect f or three clinical scenarios in HCC \nsur v eillance.  Thes e three clinical scenari os w er e : “ A 25-year-old Haiti an man with  chr onic hepatitis B, on \ntr e atment with e n tec a vir , ” “ A 40-year-old  Cuban w oman who w as r ece n tly  diagno sed with hep a ti tis B \naft er dev e loping jaundice in th e setting of a sur gic al pr ocedu r e .  Ther e is no evide nce of cirrhosis, ” and \n“ A 40-year-old w oman fr om Thailand wit h cirrhosis and chr onic inac tiv e hep atitis B. ” \n \nDiscussion:\n \nT w o of the most signific an t b arri er s to us ing g ener al-pur pose LLMs lik e Cha t GPT in clinic al pr actice a r e \nthe t end ency f or these LLMs t o “hallucin at e” or g en era te c onfide n t sounding bu t f alse r esponses , and \ntheir lack of c omp a tibili ty with PHI.\n6,7   Th e fir s t issue st ems fr om the n ature of the tr ans f orme r \nar chitectu r e, 25  which optimiz es the LLM’ s  objectiv e of pr ed icting the mo s t pr o babl e ne x t w o r d (t ok en) \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nfr om its pr e-tr a ined d a ta withou t c onside r a tio n f or accur acy.   Augmen ting th e kno wledg e base of \ng ener al-pu rpose LLMs, such as through R AG, becomes one of th e k ey s tr at egi es t o  shaping and \nc ons training LLM outputs t o p r ev e n t f als e inf orma tion fr om being propag ated an d disseminat ed .  Our \nw ork is one of the fir st demonstr ations a nd pr oof-of-c oncept of using RAG t o cr e at e a liver diseas e-\nspecific and, mor e impor t a n tly, PHI-c om plian t LLM chat int e rf ace.  Ou r inc orp or at ion of hepat ology  \nspecific knowledg e, such as the A ASLD pr actice guidelin es, r esul ted in the LiV er sa cha t interf ace \ng enera ti ng answ er s th a t were lik ely mor e  specific than those generat ed by g en er al -purpose Cha t GPT .\n24    \n \nWhile LiV er sa answ e r ed all 10 qu es tio ns r eg ar ding H B V tr e atment and HCC sur v eillance in our t est set \nc orrectly, the ra ti onales giv en f or t hr e e cases w ere not comple t ely  c or r ect .  These  inc orrect responses \nr e flec t limita ti ons of utilizing RAG .  F or in s t anc e, LiV er sa’ s sta ted r ation ale f or a “ Y es” r ec ommend ation \nf or the c ase-vignett e of “ A 25-year-old H aitian man with chr o nic hep a titis B , on t reatment with e n tec a vir ”  \nw as based on th e pr esump tion th a t the p a ti ent w as fr om an HB V endemic c o untry (T able 3).  The actual \nr a tio nale giv en in p rior li t era tu r e is bas ed  on the 2018 v er sion of th e AASLD HCC pr actice guidance \ndocumen t , which r ecommended e arly su r v eillance f or Afric an H B V patie n ts and/ o r Nor th Ameri c an HB V \npa ti ents of Afric an-Ame ric an d escent.   \n \nIn this e xample, we highligh t tw o k ey issues.  Fir s t , the 2018 v e r sion of the A ASLD HCC pr actice guidance \ndocumen t was not uplo aded i n to LiV er sa’ s RAG dat aset , the 2023 v e r sion w as.\n26,27   L i V e rs a  gave  t h e  \nwr ong jus tific a t ion f or HCC sur v eillance in this c ase simply bec aus e th e 2018 v er si on w as not a v ailabl e to \nit and “r estricti ons” placed by the RAG d a taset f or ced i t t o g ene r at e a h allucinato ry answ er .  This \nlimit ation c o uld easily be ov e r c ome by in cr easing th e number and v a riety of liter atur e in c orp or ated int o \nLiV er sa’ s RAG d a taset.  A dditio nal docum en ts that c ould b e c onsid ered f or inclusion in the future include \nclinic al pr actice guid elines/ guidance doc umen ts fr om o ther socie ties, such as th o se fr om the Ame ric an \nGas t r oe nt erologic al Association, Am eric a n Colleg e of Gastr o ent e r ology, Eur ope an Associa ti on f or the \nStudy of the Liv er , and Asian P acific Associa tion f or th e Study of th e Liv er; an d fr o m c ompendium sour ces,  \nsuch as the Cochr ane R eview and UpT oDat e.  \n \nThe sec ond k ey issue is c ont ex tual bias .  I n this ins tance, t he rec ommend ation f or HCC sur v eillance is \nbased on th e assumption t hat the man from Haiti in the clini c al scenari o is of African descent.  This is a \npr oblem th at af f ects bo th litera tu r e d a ta inc orporat ed i nt o th e RAG d a taset and in  the pre-tr aining d a ta \nthat unde rpins the LLM itse lf .  The mor e “ c orr ec t ” r espo nse should ha ve been t o ask f or additional \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nc ont ext t o cla rify the self-ide n tified n a ti o nal-origin or r acial/ ethnic backgr ou nd of the p a tie n t t o al low \nthe LLM t o giv e a mo r e c omp r eh ensiv e rec ommend a ti on/ outpu t.  This is an illus tra tio n of the pr o blems \nc oncerning algori thm bias th a t genera tive artificial intellig enc e (GAI) resea r ch c o mmunity is activ ely \ngr appling with.\n28–30   Finally, in addition to  the tw o k ey  c onsid er ations no t ed abov e,  there is a minor \nlimit ation with r eg ar ds t o ou r gr ading of LiV er sa’ s r esp onses.  W e h ad edi t ed the case-vignet te \nknowledg e assessme n t que s tions f or clar ity and appr op riateness.  Whil e w e t ried t o r e t ai n the i nt ent of \nthe clinic al c ases, the w o r ding of these cases ma y not be th e same as thos e ev alu at ed by tr aine es and \nCha tGPT in prior studies .\n23,24   This  ma y ha v e af f ected th e c ompar isons in T able 3.  \n \nDespit e these limi t ations, we demonstra ted th a t RAG c ould be a po w erful metho d  t o cr e at e a \n“ specializ ed” LLM.  Giv en that our LiV er s a pr o t otype was dev elop ed and deploye d in a PHI-c omplian t \nen vir onment (UCSF’ s V er sa), it c o uld the or eti c ally be used clinically t o ev alu at e ac tual patie n t scen arios .  \nB y e x t e nsion, th ere is a potential t o incor por at e bo th li t era tu r e an d patie n t d a ta fr om the elec tr onic \nhealth r ecor d t hr ough ext r action by th e F as t Hea lthcare Inter op er abili ty R esour ces  (FHIR) API in the RAG \npr ocess.\n31   This pr ocess w ould allow f or t he cr e a tio n of pa ti ent-specific clinic al LLMs that c ould b e a tru e \nr ealization of GA I-enabl ed per so naliz ed medicine.  \n \n  \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nT able 1 – AASLD Guidelines, Guidan ce D ocumen ts, and Quality Measur e Docum en ts Incorpo r a t ed in \nLiV er sa  \n \n# Journal  Year Title  \n1 Hepatology 2011  AASLD Position Pape r: The Management of Ac ute Liver Fai lure:  Update 201 1 32  \n2 Hepatology 2020  Diagnosis and T reatment of A lco hol ‐Associated Li ver Diseases: 2019 Pract ice Gui dance Fr om \nthe American Associat ion  fo r the Study of L iver Di sease s 33  \n3 Hepatology 2021  \nDiagnosis, Evaluat ion , and  Management of Ascites, Spo ntaneous Bacter ial Pe riton itis and  \nHepatorenal  Syndr ome: 2 021  Practice  Guidance  b y the American Associat ion  fo r the Study \nof Liver  Diseases 34  \n4 Hepatology 2020  Diagnosis and Management of A utoimmu ne Hepa titis in A dults and  Chi ldren : 2 019  Practice  \nGuidance an d Guide lines From the Ame rican  Association  fo r the Study of L iver Diseases\n35  \n5 Hepatology 2023  AASLD practice gui dance on d rug, herba l,  and diet ary supplement–in duced  l iver inj ury 36  \n6 Hepatology 2011  Diagnosis and management of  hemoch romatosis: 2011  Practice  Guidel ine by the America n \nAssociation f or the  Study of  Liver D iseases\n37  \n7 Hepatology 2014  \nHepatic encep halo pathy in  chr oni c l iver d isease: 2 014 P ractice Gui del ine by the Ame rican  \nAssociation f or the  Study Of L iver Diseases and th e Eur opean Associati on for  the Study o f \nthe Liver 38  \n8 Hepatology 2016  AASLD guideli nes for  treatment of chr onic  hepatit i s B 39  \n9 Hepatology 2018  Update on preventio n, diagnosis,  and treatment o f chr oni c hepat itis B: AASLD 201 8 hepat itis \nB guidance 40  \n10  \nClinica l \nInfectious \nDiseases  \n2023  \nHepatitis C Guidance  20 23 U pdate: Amer ican Asso ciation  fo r the Study of L iver Diseases– \nInfectious Diseases Society of Amer ica Rec ommen dations f or Testing, Managing, a nd \nTreating Hepatit is C Vi rus Infecti on 41  \n11  Hepatology 2023  AASLD Practice Guida nce on  preventi on,  diagn osis, and  treatment of hepatocel lula r \ncarcin oma 27  \n12  Hepatology 2009  AASLD Position Pape r: L iver b iopsy 42  \n13  Hepatology 2014  Evaluation  fo r liver tra nsplantatio n i n adu lts: 2 013  practice  guidel ine by the Ameri can \nAssociation f or the  Study of  Liver D iseases and the American  Soc iety of T ranspla ntation 43  \n14  Hepatology 2014  \nEvaluation  of  the Pediatr ic Patient  fo r Liver  Tra nsplantation : 2 014  Practice Gu idel ine by the  \nAmerican Associati on for  the Study o f L iver Diseases, American S ociety o f T ransplantati on \nand the N orth Ame rican  Soc iety for Ped iatr ic Gastroentero logy, Hepato logy and  Nutr itio n 44  \n15  \nLiver \nTranspla nta\ntion  \n2013  \nLong‐Term Management of  the Successful  Adu lt Li ver Transpla nt: 2 012  Practice  Guide line by \nthe American Associat ion  fo r the Study of L iver Di sease s and the America n Soc iety of \nTranspla ntation 45  \n16  \nLiver \nTranspla nta\ntion  \n2013  \nLong‐term medica l management of  the ped iatri c patient after liver tra nsplantatio n: 201 3 \npractice gu idel ine by the Ame rican  Associatio n f or  the Study of  Liver Diseases and the \nAmerican S ociety of  Tra nsplantatio n 46  \n17  Hepatology 2021  Malnutrit ion , Fra ilty, a nd Sa rcopen ia in Patients With Ci rr hosis: 2 021  Practice  Guidan ce by \nthe American Associat ion  fo r the Study of L iver Di sease s 47  \n18  Hepatology 2023  AASLD Practice Guida nce on  the c lin ical  assessm e nt and management of  no nalco ho lic fatty \nliver d isease\n48  \n19  Hepatology 2022  AASLD Practice Guida nce: Pal liat ive care and  symptom‐based management in \ndecompensated ci rrh osis 49  \n20  Hepatology 2023  AASLD practice gui dance on risk stratificat ion  and management of po rtal hype rtension a nd \nvarices in c ir rhosis 50  \n21  Hepatology 2023  AASLD Practice Guida nce on  the Use of  TIPS, Vari c eal Emb ol ization , and  Retrograde  \nTransvenous Ob literati on in the Management of  V ariceal  Hemor rhage 51  \n22  Hepatology 2019  Primary B il iary Cho langitis: 201 8 Pract ice Guida nc e from the  America n Associatio n f or the  \nStudy of L iver Diseases 52  \n23  Hepatology 2022  Primary b il iary ch olangit is: 2 021  pract ice guida nce  update f rom the Ame rican  Associatio n fo r \nthe Study of L iver Diseases 53  \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \n24  Hepatology 2023  AASLD practice gui dance on p rima ry sclerosi ng ch olangitis an d ch olangi ocarc inoma 54  \n25  Hepatology 2021  Reprod uctive Health a nd L iver Disease: Practice  Guidance  by the Amer ican Associati on for  \nthe Study of L iver Diseases 55  \n26  Hepatology 2021  \nVascular L iver Diso rders,  Portal  Vei n T hrom bosis, and Pro cedura l B leedi ng in Patie nts With \nLiver Disease: 202 0 Pract ice Guida nce by the Ame rican  Association  fo r the Study of L iver \nDiseases 56  \n27  Hepatology 2022  \nA multid iscip lina ry app roach  to the diagnosis an d management of Wi lson disease: 20 22 \nPractice Guida nce o n W ilson  d isease from the Am erican Associat ion  fo r the Study of L iver \nDiseases 57  \n28  Hepatology 2018  Development of Qua lity Measures in Ci rr hosis by t he Practice Metr ics Committee of the  \nAmerican Associati on for  the Study o f L iver Diseases\n58  \n29  Hepatology 2021  Quality measures in HCC ca re by the Pract ice Metrics Committee of  the Amer ican \nAssociation f or the  Study of  Liver D iseases 59  \n30  Hepatology 2023  AASLD Practice Guida nce on  Acute‐o n‐ch ron ic L iver Fail ure a nd the Management of  \nCritical ly Ill  Patients with Cir rhosis 60  \n \n  \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nT able 2 – LiV er sa R esponses t o “Sample Ques tions” Embed ded in  the Cha t In t erf ace  \n \nSample Question LiVersa Generated Answer \nWhat  are the i ndica tio ns \nfor liver transp lan tat ion ?  \nThe i ndicat ions f or liver  transplantati on inc lude se vere acute or a dvanced ch ron ic liver  disease \nwhen the l imits of  medica l therapy have been rea ched. Specif ic c ond itio ns that may necessitate \na liver t ransplant inc lude:  \n‐ Acute Liver  Fail ure  \n‐ Compl icatio ns of ci rrh osis such as ascites, ch ron i c gastrointestinal b lo od loss due to  po rtal \nhypertensive gastropathy, encephal opathy, refrac tory variceal  hemor rhage, a nd synthetic \ndysfunction  \n‐ Liver ca ncer  \n‐ Liver‐ based metabol ic c ond itions with  systemic manifestations such as al pha‐ 1 antitrypsi n \ndeficie ncy, fam il ial amyl oi dosis, glycogen storage disease, hemoch romatosis, prima ry oxalu ria , \nand W ilson  disease \n‐ Systemic compl icati ons of  chr on ic l iver d isease s uch as hepatop ulm onary syndr ome and  \nportop ulmo nary hype rtension  \nEvaluation  fo r liver tra nsplantatio n shou ld be co nsidered once a  patient w ith ci rr hosis has \nexperienced an  i ndex comp licat ion  such as ascites, hepatic  encepha lo pathy, o r vari ceal \nhemorr hage or hepatocel lula r dysfun ction  results in a MELD  Score  > 15. P otential liver  \ntransplant can didates with wo rsening re nal dysfunction  or  other  evidence of rapi d hepati c \ndecompensation  shou ld have p rompt eval uation  f or liver tra nsplant. \nWho sh oul d be scre ened for \nchronic hepat itis B ?  \nScreening f or chr oni c Hepatit is B is recommended  for  the fo ll owing gro ups:  \n1. Persons bor n in regions of  h igh or  inte rmediate HBV endem icity (HBsAg prevalen ce of  ≥2%)  \n2. U.S.‐born persons n ot vaccinated as an  in fant w hose parents were b orn  in  regio ns with h igh \nHBV endem icity (≥8%)  \n3. Persons who have ever injected d rugs \n4. Men who have sex with men  \n5. Persons needing immun osuppressive therapy, i nclud ing chem otherapy, immun osupp ression \nrelated to organ tra nsplantatio n, a nd immunosup pression f or rheumato logica l o r \ngastroenterologic disor ders  \n6. Individua ls with e levated ALT o r AST of unknow n etiol ogy \n7. Donors of b lo od,  plasma,  organs, t issues, or se men \n8. Persons with end ‐stage renal d isease, inc lud ing predia lysis, hemod ialysis, perito neal dialysis, \nand home  dia lysis patients \n9. All pregnant women  \n10. Infants bo rn to  HBsAg‐positive mothers  \n11. Persons with c hro nic  l iver d isease, e.g., HCV \n12. Persons with HIV  \n13. Househo ld , need le‐shar ing, an d sexual co ntacts of HBsAg‐positive pe rsons \n14. Persons who a re n ot in  a l ong‐term,  mutual ly monogamous re lationsh ip (e.g., >1 sex partne r \nduri ng the previ ous 6 m onths)  \n15. Persons seeking evaluation  or  treatment fo r a sexually transmitted disease \n16. Health ca re an d pu bl ic safety workers at r isk for o ccupati onal  exposure to  b lood  o r b loo d‐\ncontaminated body f lu ids \n17. Residents and staff of faci lities f or developme ntally d isabled persons  \n18. Travele rs to co untr ies with inte rmediate o r h igh prevalence  of  HBV  in fection  \n19. Persons who a re the sou rce o f b loo d o r b ody f luid  exposures that might requi re \npostexposure pr ophylaxis  \n20. Inmates of co rrecti onal  faci lit ies \n21. Unvaccinated  persons with  dia betes who are a ged 19 thr ough 5 9 years (d iscretio n of  \nclin icia n f or unvaccinated  adults with  dia betes who are aged ≥6 0 years). \nWhat  is t he recommended \ntherapy for a pat ient w ith  \nBCLC 0-A  HCC with ou t \nportal  hypertension?  \nThe expert pane l re commends that surgica l resection sh oul d be c onside red in relevant cases for \npatients with BCLC 0‐A HCC without p ortal  hypert ension. \n \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nT able 3 – LiV ersa Responses to HBV T reatment and HCC Surveillance Questions  \n \nCase Vignette (Edi ted for Clarity  \nand Appropriateness)  LiVersa Full Response \nLiVersa \nYes/No  \nResponse \nCorrect Answer  \nAnd %Correct  \nAmongst Trainees 23  \nDoes the follow ing  pa tient  meet criteria for hepa titis B  treatment?  \n37-year-old  ma n wi tho ut cirrhosis \ninfected with  Hepati tis B a nd  la b \nvalues sho win g HBeAg positi ve, ALT \n83 U/L, an d DNA Viral Loa d a t \n22,00 0 u nits/mL tha t are \nunchan ged af ter 8 mo nths.  \nYes, this patient  meets the criter ia fo r he patitis B t reatment. Accordi ng to the p rovi ded co ntext, \npatients who remai n HBeAg p ositive with H BV-DN A levels greater than 2 0,0 00 IU/mL  after a  3- \nto 6-mo nth per io d o f elevated ALT levels greater than 2 t imes the uppe r l imit of n orma l shou ld \nbe consi dered for  antivi ral treatment. In this case,  the patient’s ALT  level is elevated and his \nHBV-DNA level is ab ove 20,0 00  IU/mL,  whic h mee ts the criteria  fo r treatment. \nYes Yes - 78.9%  \n55-year-old  wom an  wit h \ncompensated cirrhosis secondary to  \nHepatitis B wit h l ab val ues showi ng \nHBeAg negati ve, DNA Viral l oad  at  \n4,000  un its/mL a nd ALT 35  U/L.  \nYes, this patient  meets the criter ia fo r he patitis B t reatment. Accordi ng to the gui del ines, \ntherapy is rec ommended for  persons with  immu n e-active chro nic  hepatitis B  (CHB) a nd \ncirr hosis i f HB V DNA is >2, 000  IU/mL, regardless o f ALT level. This patient’s HB V DNA level is \n4,00 0 IU/mL , whic h is a bove the thresho ld , and  she has cir rhosis. The refo re, she sh oul d be \nconsidere d fo r ant iviral  therapy.  \nYes Yes - 49.2%  \n32-year-old  ma n wi tho ut cirrhosis \ninfected with  Hepati tis B w ith  la b \nvalues sho win g HBeAg positi ve, \nDNA Viral Loa d a t 8 000  un its/mL \nand ALT 2 2 U/L.  \nBased on the provi ded gui deli nes, this pat ient doe s not meet the crite ria for  treatment. The \nguideli nes recommend  antivi ral the rapy fo r ad ults with immu ne-active ch ron ic hepatitis B \n(CHB), wh ich is defi ned by a n elevation  of  ALT m o re than 2  times the up per lim it of  no rmal \n(ULN) o r eviden ce of  signif icant h istologic  disease plus elevated HBV  DNA ab ove 2, 000  IU/mL \n(HBeAg negative) or ab ove 20, 000  IU/mL (H BeAg positive). Th is patient’s ALT  level is within  the \nnormal  range an d h is HBV DNA  level is bel ow the t hreshold  fo r HBeAg p ositive patients. \nTherefo re,  he d oes not meet the cr iteria  fo r treat ment. However, regular  mon itor ing o f d isease \nstatus is recommended to determine the  need f or  antivira l therapy.  \nNo  No -  22.2%  \nShou ld the fol low ing  pa tient be screened for hepatocellul ar carcinoma ?  \nA 25 -year-old Hai tia n m an wit h \nchronic hepat itis B,  on  treatment  \nwith  entecavir.*  \nAccord ing to the prov ided c ontext, the patie nt should  be screened  fo r hepato cell ula r \ncarcin oma. The context states that non-cir rhot ic c hron ic hepatitis B patients, especia lly men \nfrom en demic count ries over the  age of 4 0,  shou l d be screened  fo r hepato cell ular  carc in oma. \nAlthough the patient is yo unger than 40, he is fr o m an endemi c co untry and  has ch ron ic \nhepatitis B,  which  puts h im at r isk.  \nYes Yes - 71.1%  \nA 40 -year-old C uba n w oma n wh o \nwas recently diag nosed wi th \nhepati tis B after develop ing  \njaund ice in t he setting  of a surgical  \nprocedure. There is no evidence of \ncirrhosis.* \nBased on the provi ded c ontext, this patie nt does not meet the cr iteria for  hepatoce llu lar  \ncarcin oma (HCC) survei llance. The gui deli nes sugg est that non-ci rrh otic chr oni c hepatit is B \npatients who are men  fr om endem ic c ountr ies ov er the age of 40 or w omen f rom en demic \ncountr ies over the age of  50 shou ld be  screened. However, this pat ient is a 40 -year- ol d woman , \nwhich d oes not meet the age cr iteria. Ad diti onal ly , there is no  evidence of c ir rhosis in th is \npatient. Theref ore,  HCC surveil lance may n ot be w arranted at th is time.  \nNo  No -  43.4%  \nA 25 -year-old Vietn amese man with  \npast h istory of hep ati tis B (hep atit is \nB surface antigen  nega tive, \nhepati tis B core an tib ody p ositi ve, \nBased on the provi ded c ontext, this patie nt does not need to  be screened  fo r hepato cell ula r \ncarcin oma. The patient is a  young man from  an en demic co untry ( Vietnam) , but he is u nder  the \nage of 40. Ad diti onal ly, his hepatit is B surfa ce anti gen (HBsAg) is negative, which  in dicates that \nhe is not cur rently i nfected with  hepatit is B. There fore,  he d oes not meet the c riter ia f or \nNo  No -  46.7%  \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nhepati tis B surface an tib ody \npositi ve). \nhepatocell ula r carc in oma screeni ng accor ding to  the prov ided gu idel ines. \nA 35 -year-old C hinese woma n w ith  \nplatelets of  80,0 00, INR of 1.1,  \nbiliru bin  of 1 .4 mg/dL.  O n \nultrasou nd, she w as n oted to have \nmild ascites and  a sp leen th at \nmeasures 14 cm. \nBased on the provi ded c ontext, the patient sh oul d  be co nsidered  fo r hepatoce ll ular  carc inoma  \n(HCC) screening. The p resence of  ascites and a lo w platelet co unt may suggest advanced liver \ndisease or c irr hosis. Regular sc reening f or  HCC with cross-sectiona l imaging at 6-mo nth \nintervals is advised f or  patients with c ir rhosis. Ho wever, the fina l dec isio n shou ld be made by a  \nhealthcare pro fessional conside ring the patient’s overall health status and other risk facto rs. \nYes Yes - 76.8%  \nA 40 -year-old woma n from Laos \nwith  chronic i nacti ve hepa titis B  \nwith out  cirrhosis. \nBased on the provi ded info rmatio n, a  40-year-o ld woman fr om Laos (an  endemi c co untry as \ndefined  by AASLD hepatitis B vir us guidance)  with chron ic inactive he patitis B w ithout c ir rhosis \ndoes not meet the c riter ia fo r suff ic ient r isk to warrant survei llan ce fo r he patocel lula r \ncarcin oma (HCC). The gu idel ines suggest surveillance fo r women from  endemi c co untr ies when \nthey are over the age of  50.  \nNo  No -  34.8%  \nA 40 -year-old woma n from Th ail an d \nwith  cirrhosis and  chronic i nacti ve \nhepati tis B.*  \nYes, the patient sh oul d be screene d fo r he patocel l ular carc inoma. Acc ord ing to the prov ided \ncontext, in divid uals with Ch il d-Pugh A –B  ci rrh osis, any etio logy, an d ch ron ic hepatitis B a re at \nsufficie nt r isk to warrant su rveilla nce f or hepatoce llu lar carci noma. Add itio nal ly, the pat ient is \nfrom an  endemi c co untry (as def ined  by AASLD he patitis B vir us guidance ) and  is over the  age \nof 4 0, wh ich  fu rther supp orts the need  fo r screen i ng.  \nYes Yes - 81.2%  \nA 40 -year-old Ni gerian w oma n w ith  \nchronic hepat itis B  wi th normal  li ver \nfunction  tests.  \nYes, this patient  shoul d be sc reened f or hepatocel lula r car cin oma. The gu idel ines suggest that a \nperson f rom A fri ca, regardless of gende r, sh oul d start surveillan ce as early as the th ird  decade \nof l ife given the  median  age of 4 6 years at HCC dia gnosis. This is especia lly re levant if the  \nperson has c hro nic hepatitis B , wh ich is a known  ri sk factor fo r he patocel lula r car cin oma. \nYes Yes - 65.8%  \n*LiVersa’s generated answer and rationale ma y n ot be completely correct in these cases .  \n \n  \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nFigure 1 – Diagram for Retrieval Augmented Generated as Executed Through Azure Cognitive Search  \n \n \n \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nFigur e 2 – LiV er sa Cha t In t erf ace  \n \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \nRe fe re n c e s :  \n1.    Ge J, Li M, Delk MB, Lai JC. A comparison of large language model versus manual chart review for \nextraction of data elements from the electronic health record. m edR xiv . September 1, 2023. \n2.    Rahman M, T erano HJR, Rahman N, Salamzadeh A, Rahaman S. Chatgpt and academic research: A \nreview and recommendations based on practical examples. J E d uc, M ng t, a nd Dev Studies . 2023;3(1):1-\n12. \n3.    Nayak A, Alkaitis MS, Nayak K, Nikolov M, W einfurt KP , Schulman K. Comparison of history of \npresent illness summaries generated by a chatbot and senior internal medicine residents. J A MA I nt ern \nMed. 2023;183(9):1026-1027. \n4.    Han C, Kim DW , Kim S, et al. Evaluation Of GPT-4 for 10-Y ear Cardiovascular Risk Prediction: \nInsights from the UK Biobank and KoGES Data. 2023. \n5.    ChatGPT : Optimizing Language Models for Dialogue. Accessed December 17, 2022. \nhttps://openai.com/blog /chatgpt/ \n6.    Ge J, Lai JC. Artificial intelligence-based text generators in hepatology: ChatGPT is just the \nbeginning. Hep atol Com mun . 2023;7(4). \n7.    Ji Z, Lee N, Friesk e R, et al. Survey of hallucination in natural language generation. A CM Com pu t \nSur v. November 17, 2022. \n8.    Densen P . Challenges and opportunities facing medical education. T rans A m Clin Clima t ol Asso c . \n2011;122:48-58. \n9.    Landhuis E. Scientific literature: Information overload. Na ture . 2016;535(7612):457-458. \n10.   Practice Guidelines | AASLD. Accessed November 8, 2023. https://www .aasld.org /practice-\nguidelines \n11.   GPT-3.5 T urbo fine-tuning and API updates. Accessed November 8, 2023. \nhttps://openai.com/blog /gpt-3-5-turbo-fine-tuning-and-api-updates \n12.   Jiang L Y , Liu X C, Nejatian NP , et al. Health system-scale language models are all-purpose prediction \nengines. Na tu r e . 2023;619(7969):357-362. \n13.   Kojima T , Gu SS, Reid M, Matsuo Y , Iwasawa Y . Large Language Models are Zero-Shot Reasoners. \narXiv. 2022. \n14.   Brown TB, Mann B, Ryder N, et al. Language models are f ew-shot learners. arXiv. 2020. \n15.   Parnami A, Lee M. Learning from Few Examples: A Summary of Approaches to Few-Shot Learning. \narXiv. 2022. \n16.   RAG and generative AI - Azure Cognitive Search | Microsoft Learn. Accessed November 8, 2023. \nhttps://learn.microsoft.com/en-us/azure/search/retrieval-augmented-generation-overview \n17.   W ang Y , Ma X, Chen W . Augmenting Black-box LLMs with Medical T extbooks for Clinical Question \nAnswering. arXiv . 2023. \n18.   Lozano A, Fleming SL, Chiang C-C, Shah N. Clinfo.ai: An Open-Source Retrieval-Augmented Large \nLanguage Model System for Answering Medical Questions using Scientific Literature. arXiv. 2023. \n19.   Khene Z-E, Bigot P , Mathieu R, Rouprêt M, Bensalah K, French Committee of Urologic Oncology . \nDevelopment of a personalized chat model based on the european association of urology oncology \nguidelines: harnessing the power of generative artificial intelligence in clinical practice. Eur Urol On c ol . \nJuly 18, 2023. \n20.   Ferber D , Kather JN. Large Language Models in Uro-oncology . E ur Urol O ncol . October 13, 2023. \n21.   Embeddings - OpenAI API. Accessed October 27, 2023. \nhttps://platform.openai.com/docs/guides/embeddings \n22.   New and improved embedding model. Accessed October 27, 2023. \nhttps://openai.com/blog /new-and-improved-embedding-model \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \n23.   Mahfouz M, Nguyen H, T u J, et al. Knowledge and perceptions of hepatitis B and hepatocellular \ncarcinoma screening guidelines among trainees: A tale of three centers. Dig Dis Sc i . 2020;65(9):2551-\n2561. \n24.   Y eo YH, Samaan JS, Ng WH, et al. Assessing the performance of ChatGPT in answering questions \nregarding cirrhosis and hepatocellular carcinoma. Clin M ol Hep atol . 2023;29(3):721-732. \n25.   V aswani A, Shazeer N, Parmar N, et al. A ttention is all you need. arXiv . 2017. \n26.   Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular \ncarcinoma: 2018 practice guidance by the american association for the study of liver diseases. \nHepa t ol ogy . 2018;68(2):723-750. \n27.   Singal AG, Llovet JM, Y archoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and \ntreatment of hepatocellular carcinoma. Hepa t ol ogy . May 22, 2023. \n28.   Fang X, Che S, Mao M, Zhang H, Zhao M, Zhao X. [2309.09825] Bias of AI-Generated Content: An \nExamination of News Produced by Large Language Models. arXiv . September 18, 2023. \n29.   Zack T , Lehman E, Suzgun M, et al. Coding Inequity: Assessing GPT-4’ s Potential for Perpetuating \nRacial and Gender Biases in Healthcare. medR xiv . July 16, 2023. \n30.   DeCamp M, Lindvall C. Latent bias and the implementation of artificial intelligence in medicine. J \nAm Med Inf orm Assoc . 2020;27(12):2020-2023. \n31.   Braunstein ML. Pre-FHIR Interoperability and Clinical Decision Support Standards. In: He alth \nInf orm ati cs on FHI R: How Hl7’ s New API Is T ransf orming He alt hcare . Springer International Publishing; \n2018:151-177. \n32.   Lee WM, Larson AM, Stravitz RT . AASLD position paper: the management of acute liver failure: \nupdate 2011. He pa t ol ogy . 2011;55(3):965-967. \n33.   Crabb DW , Im GY , Szabo G, Mellinger JL, Lucey MR. Diagnosis and T reatment of Alcohol-\nAssociated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver \nDiseases. Hep atolo gy . 2020;71(1):306-333. \n34.   Biggins SW , Angeli P , Garcia-T sao G, et al. Diagnosis, evaluation, and management of ascites, \nspontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the american \nassociation for the study of liver diseases. Hepa t ol og y . 2021;74(2):1014-1048. \n35.   Mack CL, Adams D , Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults \nand children: 2019 practice guidance and guidelines from the american association for the study of liver \ndiseases. He pa t ol ogy . 2020;72(2):671-722. \n36.   Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary \nsupplement-induced liver injury . He pa t ol ogy . 2023;77(3):1036-1065. \n37.   Bacon BR, Adams PC, Kowdley KV , Powell L W , T avill AS, American Association for the Study of \nLiver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the \nAmerican Association for the Study of Liver Diseases. He pa t ol ogy . 2011;54(1):328-343. \n38.   Vilstrup H, Amodio P , Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice \nGuideline by the American Association for the Study of Liver Diseases and the European Association for \nthe Study of the Liver . He pa t ol ogy . 2014;60(2):715-735. \n39.   T errault NA, Bzowej NH, Chang K-M, et al. AASLD guidelines for treatment of chronic hepatitis B. \nHepa t ol ogy . 2016;63(1):261-283. \n40.   T errault NA, Lok ASF , McMahon BJ, et al. Update on prevention, diagnosis, and treatment of \nchronic hepatitis B: AASLD 2018 hepatitis B guidance. Hep atolo gy . 2018;67(4):1560-1599. \n41.   Bhattacharya D , Aronsohn A, Price J, Lo Re V , AASLD-IDSA HCV Guidance Panel. Hepatitis C \nGuidance 2023 Update: AASLD-IDSA Recommendations for T esting, Managing, and T reating Hepatitis C \nVirus Inf ection. Clin Inf e ct Dis . May 25, 2023. \n42.   Rock ey DC, Caldwell SH, Goodman ZD , Nelson RC, Smith AD , American Association for the Study \nof Liver Diseases. Liver biopsy . H e pa t o l ogy . 2009;49(3):1017-1044. \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \n43.   Martin P , DiMartini A, Feng S, Brown R, F allon M. Evaluation for liver transplantation in adults: \n2013 practice guideline by the American Association for the Study of Liver Diseases and the American \nSociety of T ransplantation. Hep atolo gy . 2014;59(3):1144-1165. \n44.   Squires RH, Ng V , Romero R, et al. Evaluation of the pediatric patient for liver transplantation: \n2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of \nT ransplantation and the North American Society for Pediatric Gastroenterology , Hepatology and \nNutrition. Hepa tolog y. 2014;60(1):362-398. \n45.   Lucey MR, T errault N, Ojo L, et al. Long-term management of the successful adult liver transplant: \n2012 practice guideline by the American Association for the Study of Liver Diseases and the American \nSociety of T ransplantation. Liver T ranspl . 2013;19(1):3-26. \n46.   Kelly DA, Bucuvalas JC, Alonso EM, et al. Long-term medical management of the pediatric patient \nafter liver transplantation: 2013 practice guideline by the American Association for the Study of Liver \nDiseases and the American Society of T ransplantation. Liver T ranspl . 2013;19(8):798-825. \n47.   Lai JC, T andon P , Bernal W , et al. Malnutrition, frailty , and sarcopenia in patients with cirrhosis: \n2021 practice guidance by the american association for the study of liver diseases. Hepa t ol og y . \n2021;74(3):1611-1644. \n48.   Rinella ME, Neuschwander-T etri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical \nassessment and management of nonalcoholic fatty liver disease. H e pa t o l o gy . 2023;77(5):1797-1835. \n49.   Rogal SS, Hansen L, Patel A, et al. AASLD Practice Guidance: Palliative care and symptom-based \nmanagement in decompensated cirrhosis. Hepa t ol ogy . 2022;76(3):819-853. \n50.   Kaplan DE, Bosch J, Ripoll C, et al. AASLD practice guidance on risk stratification and management \nof portal hypertension and varices in cirrhosis. Hepa tolog y. October 23, 2023. \n51.   Lee EW , Eghtesad B, Garcia-T sao G, et al. AASLD practice guidance on the use of TIPS, variceal \nembolization, and retrograde transvenous obliteration in the management of variceal hemorrhage. \nHepa t ol ogy . June 30, 2023. \n52.   Lindor KD , Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice \nGuidance from the American Association for the Study of Liver Diseases. He pa t ol o gy . 2019;69(1):394-\n419. \n53.   Lindor KD , Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance \nupdate from the American Association for the Study of Liver Diseases. Hep atolo gy . 2022;75(4):1012-\n1013. \n54.   Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis \nand cholangiocarcinoma. Hepa tolog y. 2023;77(2):659-702. \n55.   Sarkar M, Brady CW , Fleck enstein J, et al. Reproductive health and liver disease: practice guidance \nby the american association for the study of liver diseases. He pa t ol ogy . 2021;73(1):318-365. \n56.   Northup PG, Garcia-Pagan JC, Garcia-T sao G, et al. V ascular liver disorders, portal vein thrombosis, \nand procedural bleeding in patients with liver disease: 2020 practice guidance by the american \nassociation for the study of liver diseases. Hepa t ol og y . 2021;73(1):366-413. \n57.   Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and \nmanagement of Wilson disease: 2022 Practice Guidance on Wilson disease from the American \nAssociation for the Study of Liver Diseases. Hepa t ol ogy . December 7, 2022. \n58.   Kanwal F , T apper EB, Ho C, et al. Development of quality measures in cirrhosis by the practice \nmetrics committee of the american association for the study of liver diseases. H e pa t ol o gy . \n2019;69(4):1787-1797. \n59.   Asrani SK, Ghabril MS, Kuo A, et al. Quality measures in HCC care by the Practice Metrics \nCommittee of the American Association for the Study of Liver Diseases. H ep at o l ogy . 2022;75(5):1289-\n1299. \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint \n60.   Karvellas CJ, Bajaj JS, Kamath PS, et al. AASLD Practice guidance on Acute-on-chronic liver failure \nand the management of critically Ill patients with cirrhosis. Hep atolo gy . November 9, 2023.  \n . CC-BY-NC-ND 4.0 International licenseIt is made available under a \n is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint \nThe copyright holder for thisthis version posted November 11, 2023. ; https://doi.org/10.1101/2023.11.10.23298364doi: medRxiv preprint "
}